Référentiel des médicaments
Eltrombopag
Eltrombopag is a medicine in the class miscellaneous. It is used for aplastic anemia.
- Classe médicamenteuse: Miscellaneous
- Indications: aplastic anemia
Dernière mise à jour
Réservé aux professionnels de santé — à titre de référence uniquement. Cette page est un bref résumé, pas un avis médical, et ne remplace ni la notice officielle ni le jugement clinique. Vérifiez toujours avant de prescrire ou de délivrer.
Le contenu clinique de cette page n'est disponible qu'en anglais.
L'essentiel
- Classe médicamenteuse
- Miscellaneous
- Code ATC
- B02BX05
- Formes courantes
- comprimé, suspension buvable
- Dosages courants
- 50 mg, 25 mg
- Interactions connues
- 124 (Modérée: 66 · Mineure: 58)
- Noms commerciaux
- 14
- Pays et marchés
- 5
Indications
Mécanisme d'action
Small-molecule thrombopoietin (TPO)-receptor agonist that interacts with human TPO receptor transmembrane domain of human TPO-receptor & initiates signaling cascades that induce proliferation & differentiation of megakaryocytes from bone marrow progenitor cells
Posologie adulte habituelle (résumé de la notice)
Chronic Immune Thrombocytopenia (ITP): Initial: 50 mg PO qDay, Adjust dose to achieve and maintain platelet count (Plt) >50 x 10^9/L to reduce risk of bleeding; not to exceed 75 mg/day.
Grossesse et allaitement
- Grossesse
- Unknown Case reports are too few to assess risk; in rats, maternally toxic doses caused embryo death and lower fetal weight. EU label: not recommended in pregnancy or in women not using contraception. Use effective contraception during and for 7 days after treatment.
- Allaitement
- Unsafe No human milk data; it reached rat pups through milk. US label: breastfeeding not recommended. It clears about 8 days after the last dose. LactMed: one infant had prolonged high platelets; if used, monitor the infant's blood counts.
Effets indésirables signalés
- Headache
- Fatigue
- Upper respiratory tract infection
- Nasopharyngitis
- Nausea
- Anemia
Précautions particulières
- May develop or worsen cataracts; screen before administering and during treatment
- Thrombotic/thromboembolic complications reported; have included both venous and arterial events and were observed at low and at normal platelet counts.
- Portal vein thrombosis reported in patients with chronic liver disease receiving therapy
Informez votre pharmacien ou votre médecin en cas de grossesse ou d'allaitement, de maladie rénale ou hépatique, d'allergies, ainsi que de tout autre médicament ou complément que vous prenez.
Principales interactions (124)
- Alpelisib + Eltrombopag Moderate
- Aluminum hydroxide + Eltrombopag Moderate
- Amobarbital + Eltrombopag Moderate
- Artesunate + Eltrombopag Moderate
- Atazanavir + Eltrombopag Moderate
- Atorvastatin + Eltrombopag Moderate
- Berotralstat + Eltrombopag Moderate
- Butabarbital + Eltrombopag Moderate
- Butalbital + Eltrombopag Moderate
- Calcium + Eltrombopag Moderate
Réservé aux membres Pro+
Débloquer la page complète
Créez un compte et lancez un essai Pro+ pour ouvrir la monographie complète de Eltrombopag : posologie, grossesse et allaitement, effets indésirables, mises en garde et toutes les interactions.
- Dosing by age, kidney and liver function, and further dose lines
- Paediatric dosing
- Patient counselling points
- Food interactions
Essayez Pro+ gratuitement pendant 14 jours sur le web. Sans carte.
Questions fréquentes
What is Eltrombopag used for?
Eltrombopag is a medicine in the class miscellaneous. It is used for Aplastic anemia, Thrombocytopenia.
What side effects have been reported with Eltrombopag?
Headache, Fatigue, Upper respiratory tract infection, Nasopharyngitis, Nausea, Anemia.
Can Eltrombopag be taken in pregnancy or while breastfeeding?
Pregnancy: Unknown. Case reports are too few to assess risk; in rats, maternally toxic doses caused embryo death and lower fetal weight. EU label: not recommended in pregnancy or in women not using contraception. Use effective contraception during and for 7 days after treatment. Breastfeeding: Unsafe. No human milk data; it reached rat pups through milk. US label: breastfeeding not recommended. It clears about 8 days after the last dose. LactMed: one infant had prolonged high platelets; if used, monitor the infant's blood counts.
What does Eltrombopag interact with?
MediHelp lists 124 known interactions for Eltrombopag. Moderate: 66 · Minor: 58. The most serious include Alpelisib, Aluminum hydroxide, Amobarbital.
Monographies complètes, posologies et vérificateur d'interactions dans l'application MediHelp
Ouvrez le référentiel complet, vérifiez les interactions entre plusieurs médicaments et utilisez les outils de posologie dans l'application MediHelp.
